{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:45:49Z","timestamp":1792813549565,"version":"4.5.0"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T00:00:00Z","timestamp":1755561600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41585-025-01077-9","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T12:03:57Z","timestamp":1755605037000},"page":"40-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Urinary bladder cancer needs more attention \u2014 recommendations for health care professionals and politicians in the European Union"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-2763","authenticated-orcid":false,"given":"Thorsten H.","family":"Ecke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8407-4511","authenticated-orcid":false,"given":"Sarah","family":"Collen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8049-3438","authenticated-orcid":false,"given":"Alex","family":"Filicevas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodoros","family":"Yfantis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0063-5068","authenticated-orcid":false,"given":"Florence","family":"Le Calvez-Kelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente Thoft","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hein","family":"van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,19]]},"reference":[{"key":"1077_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer J. Clinicians 74, 229\u2013263 (2024).","journal-title":"CA: A Cancer J. Clinicians"},{"key":"1077_CR2","first-page":"29","volume":"38","author":"E Crocetti","year":"2014","unstructured":"Crocetti, E. et al. SENTIERI project: results [Italian]. Epidemiol. Prev. 38, 29\u2013124 (2014).","journal-title":"Epidemiol. Prev."},{"key":"1077_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.eururo.2015.10.024","volume":"69","author":"J Leal","year":"2016","unstructured":"Leal, J. et al. Economic burden of bladder cancer across the European Union. Eur. Urol. 69, 438\u2013447 (2016).","journal-title":"Eur. Urol."},{"key":"1077_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","volume":"77","author":"JA Witjes","year":"2020","unstructured":"Witjes, J. A. et al. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer \u2014 an International collaborative multistakeholder effort: under the auspices of the EAU-ESMO guidelines committees. Eur. Urol. 77, 223\u2013250 (2020).","journal-title":"Eur. Urol."},{"key":"1077_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.22","volume":"3","author":"O Sanli","year":"2017","unstructured":"Sanli, O. et al. Bladder cancer. Nat. Rev. Dis. Primers 3, 17022 (2017).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1077_CR6","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger, M. et al. Epidemiology and risk factors of urothelial bladder cancer. Eur. Urol. 63, 234\u2013241 (2013).","journal-title":"Eur. Urol."},{"key":"1077_CR7","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/01.ju.0000162039.38023.5f","volume":"174","author":"JE Rosenberg","year":"2005","unstructured":"Rosenberg, J. E., Carroll, P. R. & Small, E. J. Update on chemotherapy for advanced bladder cancer. J. Urol. 174, 14\u201320 (2005).","journal-title":"J. Urol."},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskj\u00f8t","year":"2023","unstructured":"Dyrskj\u00f8t, L. et al. Bladder cancer. Nat. Rev. Dis. Primers 9, 58 (2023).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"1077_CR9","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.hoc.2021.02.004","volume":"35","author":"H Ahmadi","year":"2021","unstructured":"Ahmadi, H., Duddalwar, V. & Daneshmand, S. Diagnosis and staging of bladder cancer. Hematol. Oncol. Clin. North Am. 35, 531\u2013541 (2021).","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"1077_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.urolonc.2024.01.025","volume":"42","author":"N Benderska-S\u00f6der","year":"2024","unstructured":"Benderska-S\u00f6der, N. et al. Simulation of the effects of molecular urine markers in follow-up of patients with high-risk non-muscle invasive bladder cancer. Urol. Oncol. 42, 229\u2013235 (2024).","journal-title":"Urol. Oncol."},{"key":"1077_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1111\/bju.15677","volume":"130","author":"CJ Meisl","year":"2022","unstructured":"Meisl, C. J. et al. Nomograms including the UBC\u00ae Rapid test to detect primary bladder cancer based on a multicentre dataset. BJU Int. 130, 754\u2013763 (2022).","journal-title":"BJU Int."},{"key":"1077_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.urolonc.2018.01.014","volume":"36","author":"TCM Zuiverloon","year":"2018","unstructured":"Zuiverloon, T. C. M. et al. Recommendations for follow-up of muscle-invasive bladder cancer patients: a consensus by the international bladder cancer network. Urol. Oncol. 36, 423\u2013431 (2018).","journal-title":"Urol. Oncol."},{"key":"1077_CR13","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.3390\/jpm12101745","volume":"12","author":"V Bilim","year":"2022","unstructured":"Bilim, V. et al. Advanced bladder cancer: changing the treatment landscape. J. Pers. Med. 12, 1745 (2022).","journal-title":"J. Pers. Med."},{"key":"1077_CR14","unstructured":"White Paper on Bladder Cancer: Policy Recommendations to Leverage Legislative Opportunities for Better Support of Patients and Carers Affected by Bladder Cancer in Europe (EAU, 2023)."},{"key":"1077_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A W\u00e9ber","year":"2024","unstructured":"W\u00e9ber, A. et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J. Urol. 42, 237 (2024).","journal-title":"World J. Urol."},{"key":"1077_CR16","volume":"14","author":"SA Halaseh","year":"2022","unstructured":"Halaseh, S. A. et al. A review of the etiology and epidemiology of bladder cancer: all you need to know. Cureus 14, e27330 (2022).","journal-title":"Cureus"},{"key":"1077_CR17","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC van Hoogstraten","year":"2023","unstructured":"van Hoogstraten, L. M. C. et al. Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat. Rev. Clin. Oncol. 20, 287\u2013304 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1077_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5332-x","volume":"18","author":"A Scarselli","year":"2018","unstructured":"Scarselli, A. et al. Gender differences in occupational exposure to carcinogens among Italian workers. BMC Public Health 18, 413 (2018).","journal-title":"BMC Public Health"},{"key":"1077_CR19","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1007\/s00345-019-02984-4","volume":"38","author":"A Richters","year":"2020","unstructured":"Richters, A., Aben, K. K. H. & Kiemeney, L. The global burden of urinary bladder cancer: an update. World J. Urol. 38, 1895\u20131904 (2020).","journal-title":"World J. Urol."},{"key":"1077_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s40266-018-0540-8","volume":"35","author":"G Jodon","year":"2018","unstructured":"Jodon, G., Fischer, S. M. & Kessler, E. R. Treatment of urothelial cancer in elderly patients: focus on immune checkpoint inhibitors. Drugs Aging 35, 409\u2013421 (2018).","journal-title":"Drugs Aging"},{"key":"1077_CR21","doi-asserted-by":"publisher","DOI":"10.1177\/10732748231152322","volume":"30","author":"W Lin","year":"2023","unstructured":"Lin, W. et al. Impact of age at diagnosis of bladder cancer on survival: a surveillance, epidemiology, and end results-based study 2004\u20132015. Cancer Control 30, 10732748231152322 (2023).","journal-title":"Cancer Control"},{"key":"1077_CR22","first-page":"939","volume":"10","author":"EA Guancial","year":"2015","unstructured":"Guancial, E. A. et al. Bladder cancer in the elderly patient: challenges and solutions. Clin. Interv. Aging 10, 939\u2013949 (2015).","journal-title":"Clin. Interv. Aging"},{"key":"1077_CR23","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1007\/s11255-023-03897-3","volume":"56","author":"W Zhu","year":"2024","unstructured":"Zhu, W. et al. Comparison of morbidity and mortality after radical cystectomy between individuals older and younger than 80 years: a systematic review and meta-analysis. Int. Urol. Nephrol. 56, 1525\u20131535 (2024).","journal-title":"Int. Urol. Nephrol."},{"key":"1077_CR24","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jama.2011.1142","volume":"306","author":"ND Freedman","year":"2011","unstructured":"Freedman, N. D. et al. Association between smoking and risk of bladder cancer among men and women. JAMA 306, 737\u2013745 (2011).","journal-title":"JAMA"},{"key":"1077_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.eururo.2020.09.006","volume":"78","author":"JY Teoh","year":"2020","unstructured":"Teoh, J. Y. et al. Global trends of bladder cancer incidence and mortality, and their associations with tobacco use and gross domestic product per capita. Eur. Urol. 78, 893\u2013906 (2020).","journal-title":"Eur. Urol."},{"key":"1077_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/030089160709300102","volume":"93","author":"S Jankovi\u0107","year":"2007","unstructured":"Jankovi\u0107, S. & Radosavljevi\u0107, V. Risk factors for bladder cancer. Tumori 93, 4\u201312 (2007).","journal-title":"Tumori"},{"key":"1077_CR27","unstructured":"OECD\/European Commission. EU Country Cancer Profiles Synthesis Report 2025 (OECD Publishing, 2025)."},{"key":"1077_CR28","unstructured":"WHO Framework Convention on Tobacco Control (WHO, 2003)."},{"key":"1077_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/s41370-024-00651-4","volume":"34","author":"S Xie","year":"2024","unstructured":"Xie, S. et al. Occupational exposure to organic solvents and risk of bladder cancer. J. Expo. Sci. Env. Epidemiol. 34, 546\u2013553 (2024).","journal-title":"J. Expo. Sci. Env. Epidemiol."},{"key":"1077_CR30","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1093\/ije\/dyx146","volume":"46","author":"M Boniol","year":"2017","unstructured":"Boniol, M., Koechlin, A. & Boyle, P. Meta-analysis of occupational exposures in the rubber manufacturing industry and risk of cancer. Int. J. Epidemiol. 46, 1940\u20131947 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"1077_CR31","first-page":"96","volume":"43","author":"LD Marrett","year":"1986","unstructured":"Marrett, L. D., Hartge, P. & Meigs, J. W. Bladder cancer and occupational exposure to leather. Br. J. Ind. Med. 43, 96\u2013100 (1986).","journal-title":"Br. J. Ind. Med."},{"key":"1077_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12995-016-0128-3","volume":"11","author":"Z Singh","year":"2016","unstructured":"Singh, Z. & Chadha, P. Textile industry and occupational cancer. J. Occup. Med. Toxicol. 11, 39 (2016).","journal-title":"J. Occup. Med. Toxicol."},{"key":"1077_CR33","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/jamaoncol.2015.3209","volume":"1","author":"MG Cumberbatch","year":"2015","unstructured":"Cumberbatch, M. G. et al. Contemporary occupational carcinogen exposure and bladder cancer: a systematic review and meta-analysis. JAMA Oncol. 1, 1282\u20131290 (2015).","journal-title":"JAMA Oncol."},{"key":"1077_CR34","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1002\/ijc.23194","volume":"122","author":"E Dryson","year":"2008","unstructured":"Dryson, E. et al. Case-control study of high risk occupations for bladder cancer in New Zealand. Int. J. Cancer 122, 1340\u20131346 (2008).","journal-title":"Int. J. Cancer"},{"key":"1077_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni, S. et al. Bladder cancer incidence and mortality: a global overview and recent trends. Eur. Urol. 71, 96\u2013108 (2017).","journal-title":"Eur. Urol."},{"key":"1077_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016538","volume":"7","author":"K Hadkhale","year":"2017","unstructured":"Hadkhale, K. et al. Occupational variation in incidence of bladder cancer: a comparison of population-representative cohorts from Nordic countries and Canada. BMJ Open 7, e016538 (2017).","journal-title":"BMJ Open"},{"key":"1077_CR37","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1016\/j.eururo.2012.12.062","volume":"63","author":"S Larr\u00e9","year":"2013","unstructured":"Larr\u00e9, S. et al. Screening for bladder cancer: rationale, limitations, whom to target, and perspectives. Eur. Urol. 63, 1049\u20131058 (2013).","journal-title":"Eur. Urol."},{"key":"1077_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-50602-6","volume":"14","author":"W Lim","year":"2024","unstructured":"Lim, W. et al. Group I pharmaceuticals of IARC and associated cancer risks: systematic review and meta-analysis. Sci. Rep. 14, 413 (2024).","journal-title":"Sci. Rep."},{"key":"1077_CR39","doi-asserted-by":"publisher","first-page":"16001","DOI":"10.1289\/EHP14505","volume":"133","author":"E Helte","year":"2025","unstructured":"Helte, E. et al. Exposure to drinking water trihalomethanes and risk of cancer: a systematic review of the epidemiologic evidence and dose-response meta-analysis. Environ. Health Perspect. 133, 16001 (2025).","journal-title":"Environ. Health Perspect."},{"key":"1077_CR40","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0094-0143(21)00411-0","volume":"19","author":"NM Heney","year":"1992","unstructured":"Heney, N. M. Natural history of superficial bladder cancer. Prognostic features and long-term disease course. Urol. Clin. North Am. 19, 429\u2013433 (1992).","journal-title":"Urol. Clin. North Am."},{"key":"1077_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3233\/BLC-190221","volume":"5","author":"R Ghandour","year":"2019","unstructured":"Ghandour, R. et al. Evaluation of hematuria in a large public health care system. Bladder Cancer 5, 119\u2013129 (2019).","journal-title":"Bladder Cancer"},{"key":"1077_CR42","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00345-012-0979-x","volume":"30","author":"EK Cha","year":"2012","unstructured":"Cha, E. K. et al. Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. World J. Urol. 30, 847\u2013852 (2012).","journal-title":"World J. Urol."},{"key":"1077_CR43","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.eururo.2022.03.027","volume":"82","author":"BP Rai","year":"2022","unstructured":"Rai, B. P. et al. Systematic review of the incidence of and risk factors for urothelial cancers and renal cell carcinoma among patients with haematuria. Eur. Urol. 82, 182\u2013192 (2022).","journal-title":"Eur. Urol."},{"key":"1077_CR44","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","volume":"86","author":"P Gontero","year":"2024","unstructured":"Gontero, P. et al. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) \u2014 a summary of the 2024 guidelines update. Eur. Urol. 86, 531\u2013549 (2024).","journal-title":"Eur. Urol."},{"key":"1077_CR45","doi-asserted-by":"publisher","first-page":"467","DOI":"10.31128\/AJGP-03-21-5892","volume":"50","author":"E O\u2019Connor","year":"2021","unstructured":"O\u2019Connor, E. et al. Assessment and management of haematuria in the general practice setting. Aust. J. Gen. Pract. 50, 467\u2013471 (2021).","journal-title":"Aust. J. Gen. Pract."},{"key":"1077_CR46","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0090-4295(02)02136-2","volume":"61","author":"Y Lotan","year":"2003","unstructured":"Lotan, Y. & Roehrborn, C. G. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology 61, 109\u2013118 (2003). discussion 118.","journal-title":"Urology"},{"key":"1077_CR47","doi-asserted-by":"publisher","first-page":"4038","DOI":"10.7150\/jca.28989","volume":"10","author":"CZ Zhu","year":"2019","unstructured":"Zhu, C. Z. et al. A review on the accuracy of bladder cancer detection methods. J. Cancer 10, 4038\u20134044 (2019).","journal-title":"J. Cancer"},{"key":"1077_CR48","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.euo.2021.10.003","volume":"4","author":"E Laukhtina","year":"2021","unstructured":"Laukhtina, E. et al. Diagnostic accuracy of novel urinary biomarker tests in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis. Eur. Urol. Oncol. 4, 927\u2013942 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1077_CR49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/UPJ.0000000000000489","volume":"11","author":"MD Tyson","year":"2024","unstructured":"Tyson, M. D. et al. Budgetary impact of including the urinary genomic marker Cxbladder detect in the evaluation of microhematuria patients. Urol. Pract. 11, 54\u201360 (2024).","journal-title":"Urol. Pract."},{"key":"1077_CR50","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1002\/bco2.147","volume":"3","author":"NA Soputro","year":"2022","unstructured":"Soputro, N. A. et al. Utility of urinary biomarkers in primary haematuria: systematic review and meta-analysis. BJUI Compass 3, 334\u2013343 (2022).","journal-title":"BJUI Compass"},{"key":"1077_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06749-z","volume":"23","author":"I Pagano","year":"2025","unstructured":"Pagano, I. et al. Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical setting. J. Transl. Med. 23, 680 (2025).","journal-title":"J. Transl. Med."},{"key":"1077_CR52","doi-asserted-by":"publisher","first-page":"484.e17","DOI":"10.1016\/j.urolonc.2023.06.013","volume":"41","author":"TH Ecke","year":"2023","unstructured":"Ecke, T. H. et al. BTA stat\u00ae, NMP22\u00ae BladderChek\u00ae, UBC\u00ae rapid test, and CancerCheck\u00ae UBC\u00ae rapid VISUAL as urinary marker for bladder cancer: final results of a German multicenter study. Urol. Oncol. 41, 484.e17\u2013484.e26 (2023).","journal-title":"Urol. Oncol."},{"key":"1077_CR53","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/bju.16450","volume":"134","author":"I Wolff","year":"2024","unstructured":"Wolff, I. et al. Real-world performance of Uromonitor\u00ae in urothelial bladder cancer detection: a multicentric trial. BJU Int. 134, 992\u20131000 (2024).","journal-title":"BJU Int."},{"key":"1077_CR54","doi-asserted-by":"publisher","first-page":"3541","DOI":"10.3390\/cancers12123541","volume":"12","author":"MI Hosen","year":"2020","unstructured":"Hosen, M. I. et al. Development of sensitive droplet digital PCR assays for detecting urinary TERT promoter mutations as non-invasive biomarkers for detection of urothelial cancer. Cancers 12, 3541 (2020).","journal-title":"Cancers"},{"key":"1077_CR55","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1002\/cncr.22084","volume":"107","author":"Y Lotan","year":"2006","unstructured":"Lotan, Y., Svatek, R. S. & Sagalowsky, A. I. Should we screen for bladder cancer in a high-risk population?: a cost per life-year saved analysis. Cancer 107, 982\u2013990 (2006).","journal-title":"Cancer"},{"key":"1077_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-076612","volume":"13","author":"JW Catto","year":"2023","unstructured":"Catto, J. W. et al. Protocol for the YORKSURe prospective multistage study testing the feasibility for early detection of bladder cancer in populations with high disease-specific mortality risk. BMJ Open 13, e076612 (2023).","journal-title":"BMJ Open"},{"key":"1077_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-526","volume":"12","author":"AJ Carter","year":"2012","unstructured":"Carter, A. J. & Nguyen, C. N. A comparison of cancer burden and research spending reveals discrepancies in the distribution of research funding. BMC Public Health 12, 526 (2012).","journal-title":"BMC Public Health"},{"key":"1077_CR58","doi-asserted-by":"publisher","first-page":"40.e23","DOI":"10.1016\/j.urolonc.2013.04.010","volume":"32","author":"H Donsky","year":"2014","unstructured":"Donsky, H. et al. Sex differences in incidence and mortality of bladder and kidney cancers: national estimates from 49 countries. Urol. Oncol. 32, 40.e23\u201340.e31 (2014).","journal-title":"Urol. Oncol."},{"key":"1077_CR59","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1002\/cncr.28416","volume":"120","author":"JA Cohn","year":"2014","unstructured":"Cohn, J. A. et al. Sex disparities in diagnosis of bladder cancer after initial presentation with hematuria: a nationwide claims-based investigation. Cancer 120, 555\u2013561 (2014).","journal-title":"Cancer"},{"key":"1077_CR60","doi-asserted-by":"publisher","first-page":"g2171","DOI":"10.1136\/bmj.g2171","volume":"348","author":"BD Nicholson","year":"2014","unstructured":"Nicholson, B. D., McGrath, J. S. & Hamilton, W. Bladder cancer in women. BMJ 348, g2171 (2014).","journal-title":"BMJ"},{"key":"1077_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1159\/000449256","volume":"97","author":"F Burge","year":"2016","unstructured":"Burge, F. & Kockelbergh, R. Closing the gender gap: can we improve bladder cancer survival in women? \u2014 a systematic review of diagnosis, treatment and outcomes. Urol. Int. 97, 373\u2013379 (2016).","journal-title":"Urol. Int."},{"key":"1077_CR62","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41585-023-00806-2","volume":"21","author":"P Toren","year":"2024","unstructured":"Toren, P. et al. The sex gap in bladder cancer survival \u2014 a missing link in bladder cancer care? Nat. Rev. Urol. 21, 181\u2013192 (2024).","journal-title":"Nat. Rev. Urol."},{"key":"1077_CR63","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.clgc.2019.11.007","volume":"18","author":"S Kimura","year":"2020","unstructured":"Kimura, S. et al. Impact of gender on chemotherapeutic response and oncologic outcomes in patients treated with radical cystectomy and perioperative chemotherapy for bladder cancer: a systematic review and meta-analysis. Clin. Genitourin. Cancer 18, 78\u201387 (2020).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1077_CR64","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1080\/21681805.2018.1462254","volume":"52","author":"C Sj\u00f6str\u00f6m","year":"2018","unstructured":"Sj\u00f6str\u00f6m, C. et al. Treatment according to guidelines may bridge the gender gap in outcome for patients with stage T1 urinary bladder cancer. Scand. J. Urol. 52, 186\u2013193 (2018).","journal-title":"Scand. J. Urol."},{"key":"1077_CR65","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2014.01.006","volume":"66","author":"RS Svatek","year":"2014","unstructured":"Svatek, R. S. et al. The economics of bladder cancer: costs and considerations of caring for this disease. Eur. Urol. 66, 253\u2013262 (2014).","journal-title":"Eur. Urol."},{"key":"1077_CR66","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.2174\/1389557516666160512151202","volume":"20","author":"M Boegemann","year":"2020","unstructured":"Boegemann, M. & Krabbe, L. M. Prognostic implications of immunohistochemical biomarkers in non-muscle-invasive blad cancer and muscle-invasive bladder cancer. Mini Rev. Med. Chem. 20, 1133\u20131152 (2020).","journal-title":"Mini Rev. Med. Chem."},{"key":"1077_CR67","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.euf.2023.05.002","volume":"9","author":"S Katsimperis","year":"2023","unstructured":"Katsimperis, S. et al. Complications after radical cystectomy: a systematic review and meta-analysis of randomized controlled trials with a meta-regression analysis. Eur. Urol. Focus. 9, 920\u2013929 (2023).","journal-title":"Eur. Urol. Focus."},{"key":"1077_CR68","doi-asserted-by":"publisher","first-page":"3395","DOI":"10.1158\/1078-0432.CCR-23-0609","volume":"29","author":"X Duan","year":"2023","unstructured":"Duan, X. et al. First-in-human study of the radioligand 68Ga-N188 targeting Nectin-4 for PET\/CT imaging of advanced urothelial carcinoma. Clin. Cancer Res. 29, 3395\u20133407 (2023).","journal-title":"Clin. Cancer Res."},{"key":"1077_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.eururo.2025.09.2549","volume":"87","author":"TSE Ecke","year":"2025","unstructured":"Ecke, T. S. E. et al. Theranostic instillation therapy targeting CXCR4 in combination with systemic chemotherapy for muscle invasive bladder cancer \u2014 the \u201cBladder BRIDGister\u201d experience. Eur. Urol. 87, 97 (2025).","journal-title":"Eur. Urol."},{"key":"1077_CR70","doi-asserted-by":"publisher","first-page":"61.e1","DOI":"10.1016\/j.urolonc.2024.08.001","volume":"43","author":"M Finati","year":"2025","unstructured":"Finati, M. et al. Radical cystectomy versus trimodal therapy for muscle-invasive bladder cancer: analysis of an other-cause mortality matched cohort. Urol. Oncol. 43, 61.e1\u201361.e9 (2025).","journal-title":"Urol. Oncol."},{"key":"1077_CR71","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1001\/jama.2022.7393","volume":"327","author":"JWF Catto","year":"2022","unstructured":"Catto, J. W. F. et al. Effect of robot-assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy on 90-day morbidity and mortality among patients with bladder cancer: a randomized clinical trial. JAMA 327, 2092\u20132103 (2022).","journal-title":"JAMA"},{"key":"1077_CR72","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles, T. et al. Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann. Oncol. 33, 244\u2013258 (2022).","journal-title":"Ann. Oncol."},{"key":"1077_CR73","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.eururo.2020.10.011","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford, P. et al. IMAGINE-IMpact assessment of guidelines implementation and education: the next frontier for harmonising urological practice across Europe by improving adherence to guidelines. Eur. Urol. 79, 173\u2013176 (2021).","journal-title":"Eur. Urol."},{"key":"1077_CR74","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.juro.2012.11.115","volume":"189","author":"TC Zuiverloon","year":"2013","unstructured":"Zuiverloon, T. C. et al. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project. J. Urol. 189, 1945\u20131951 (2013).","journal-title":"J. Urol."},{"key":"1077_CR75","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1007\/s00432-018-2694-5","volume":"144","author":"S Rinaldetti","year":"2018","unstructured":"Rinaldetti, S. et al. FOXM1 predicts disease progression in non-muscle invasive bladder cancer. J. Cancer Res. Clin. Oncol. 144, 1701\u20131709 (2018).","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"1077_CR76","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bju.14525","volume":"123","author":"J Breyer","year":"2019","unstructured":"Breyer, J. et al. FOXM1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage pT1 non-muscle-invasive bladder cancer. BJU Int. 123, 187\u2013196 (2019).","journal-title":"BJU Int."},{"key":"1077_CR77","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.euros.2021.02.006","volume":"27","author":"S Wei\u00df","year":"2021","unstructured":"Wei\u00df, S. et al. Identifying the molecular mechanisms contributing to progression, metastasis, and death in low-grade non-muscle-invasive bladder cancer: a case report. Eur. Urol. Open Sci. 27, 29\u201332 (2021).","journal-title":"Eur. Urol. Open Sci."},{"key":"1077_CR78","doi-asserted-by":"publisher","first-page":"7898","DOI":"10.3390\/ijms23147898","volume":"23","author":"TH Ecke","year":"2022","unstructured":"Ecke, T. H. et al. Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment. Int. J. Mol. Sci. 23, 7898 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"1077_CR79","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.euros.2020.06.007","volume":"20","author":"G Ungerer","year":"2020","unstructured":"Ungerer, G. et al. Living with bladder cancer: self-reported changes in patients\u2019 functional and overall health status following diagnosis. Eur. Urol. Open Sci. 20, 14\u201319 (2020).","journal-title":"Eur. Urol. Open Sci."},{"key":"1077_CR80","unstructured":"Noll, P. Diktate \u00fcber Sterben und Tod (Pendo Verlag, 1984)."},{"key":"1077_CR81","first-page":"789","volume":"40","author":"H Gerullis","year":"2010","unstructured":"Gerullis, H. et al. What happens if nothing happens? \u2014 history of an untreated urothelial carcinoma of the bladder. J. Egypt. Soc. Parasitol. 40, 789\u2013796 (2010).","journal-title":"J. Egypt. Soc. Parasitol."},{"key":"1077_CR82","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/bju.14047","volume":"121","author":"AB Smith","year":"2018","unstructured":"Smith, A. B. et al. Impact of bladder cancer on health-related quality of life. BJU Int. 121, 549\u2013557 (2018).","journal-title":"BJU Int."},{"key":"1077_CR83","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.eururo.2023.08.016","volume":"85","author":"J Alfred Witjes","year":"2024","unstructured":"Alfred Witjes, J. et al. European Association of Urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines. Eur. Urol. 85, 17\u201331 (2024).","journal-title":"Eur. Urol."},{"key":"1077_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.eururo.2021.05.015","volume":"81","author":"LG Briggs","year":"2022","unstructured":"Briggs, L. G. et al. Prehabilitation exercise before urologic cancer surgery: a systematic and interdisciplinary review. Eur. Urol. 81, 157\u2013167 (2022).","journal-title":"Eur. Urol."},{"key":"1077_CR85","first-page":"3325","volume":"24","author":"BT Jensen","year":"2016","unstructured":"Jensen, B. T. et al. Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways-secondary results from a randomized controlled trial. Support. Care Cancer 24, 3325\u20133331 (2016).","journal-title":"Support. Care Cancer"},{"key":"1077_CR86","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3109\/21681805.2014.967810","volume":"49","author":"BT Jensen","year":"2015","unstructured":"Jensen, B. T. et al. Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. Scand. J. Urol. 49, 133\u2013141 (2015).","journal-title":"Scand. J. Urol."},{"key":"1077_CR87","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejon.2017.03.001","volume":"28","author":"BT Jensen","year":"2017","unstructured":"Jensen, B. T. et al. Efficacy of preoperative uro-stoma education on self-efficacy after radical cystectomy; secondary outcome of a prospective randomized controlled trial. Eur. J. Oncol. Nurs. 28, 41\u201346 (2017).","journal-title":"Eur. J. Oncol. Nurs."},{"key":"1077_CR88","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.eururo.2023.04.034","volume":"84","author":"LE Makaroff","year":"2023","unstructured":"Makaroff, L. E. et al. Patient and carer experiences with bladder cancer: results from a global survey in 45 countries. Eur. Urol. 84, 248\u2013251 (2023).","journal-title":"Eur. Urol."},{"key":"1077_CR89","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euros.2021.01.014","volume":"26","author":"DJ Reesink","year":"2021","unstructured":"Reesink, D. J. et al. Development of the first patient-centred set of outcomes for muscle-invasive and metastatic bladder cancer: a multicentre initiative. Eur. Urol. Open Sci. 26, 18\u201326 (2021).","journal-title":"Eur. Urol. Open Sci."},{"key":"1077_CR90","unstructured":"Patient and Carer Experiences with Bladder Cancer: Findings from a Global Survey (World Bladder Cancer Patient Coalition, 2023)."},{"key":"1077_CR91","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1007\/s11136-022-03335-4","volume":"32","author":"E Rammant","year":"2023","unstructured":"Rammant, E. et al. The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review. Qual. Life Res. 32, 2127\u20132135 (2023).","journal-title":"Qual. Life Res."},{"key":"1077_CR92","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/bco2.186","volume":"4","author":"R Martin","year":"2023","unstructured":"Martin, R. et al. Female sexual function in bladder cancer: a review of the evidence. BJUI Compass 4, 5\u201323 (2023).","journal-title":"BJUI Compass"},{"key":"1077_CR93","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.eururo.2021.01.032","volume":"79","author":"JWF Catto","year":"2021","unstructured":"Catto, J. W. F. et al. Quality of life after bladder cancer: a cross-sectional survey of patient-reported outcomes. Eur. Urol. 79, 621\u2013632 (2021).","journal-title":"Eur. Urol."},{"key":"1077_CR94","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41585-022-00693-z","volume":"20","author":"E Grobet-Jeandin","year":"2023","unstructured":"Grobet-Jeandin, E. et al. Health-related quality of life after curative treatment for muscle-invasive bladder cancer. Nat. Rev. Urol. 20, 279\u2013293 (2023).","journal-title":"Nat. Rev. Urol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01077-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T01:02:16Z","timestamp":1767747736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-025-01077-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,19]]},"references-count":94,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1038\/s41585-025-01077-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,19]]},"assertion":[{"value":"22 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}